Patents by Inventor Roger Petrus Gerebern Vandecruys

Roger Petrus Gerebern Vandecruys has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SALT OF 4-[[4-[[4-(2-CYANOETHENYL)-2,6-DIMETHYLPHENYL]AMINO]-2-PYRIMIDINYL]AMINO]BENZONITRILE
    Publication number: 20180116964
    Abstract: The present invention relates to the fumarate salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile, pharmaceutical compositions comprising as active ingredient said salt and to processes for their preparation.
    Type: Application
    Filed: December 22, 2017
    Publication date: May 3, 2018
    Inventors: Paul Theodoor Agnes Stevens, Jozef Peeters, Roger Petrus Gerebern Vandecruys, Alfred Elisabeth Stappers, Alex Herman Copmans
  • Amorphous Salt of a Macrocyclic Inhibitor of HCV
    Publication number: 20160251345
    Abstract: The amorphous form of the sodium salt of the macrocyclic inhibitor of HCV of formula: as well as processes for manufacturing this salt.
    Type: Application
    Filed: March 8, 2016
    Publication date: September 1, 2016
    Applicant: Janssen Pharmaceuticals, Inc.
    Inventors: Peter Jozef Maria Van Remoortere, Roger Petrus Gerebern Vandecruys, Herman De Kock
  • Amorphous salt of a macrocyclic inhibitor of HCV
    Patent number: 9321758
    Abstract: The amorphous form of the sodium salt of the macrocyclic inhibitor of HCV of formula: as well as processes for manufacturing this salt.
    Type: Grant
    Filed: February 26, 2010
    Date of Patent: April 26, 2016
    Assignee: Janssen Pharmaceuticals, Inc.
    Inventors: Peter Jozef Maria Van Remoortere, Roger Petrus Gerebern Vandecruys, Herman De Kock
  • Pharmaceutical compositions comprising a basic drug compound, a surfactant, and a physiologically tolerable water soluble acid
    Patent number: 9192577
    Abstract: The invention provides a novel pharmaceutical composition comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base characterized in that the acid respectively base:drug compound ratio is at least 1:1 by weight.
    Type: Grant
    Filed: November 25, 2003
    Date of Patent: November 24, 2015
    Assignee: Janssen Pharmaceutica NV
    Inventors: Roger Petrus Gerebern Vandecruys, Jozef Peeters, Marcus Eli Brewster
  • Pregelatinized starch in a controlled release formulation
    Patent number: 8591945
    Abstract: The present invention concerns the use of pregelatinized starch to prevent dose-dumping from a hydrophilic controlled release formulation. It also concerns a hydrophilic controlled release formulation, more in particular a hydrophilic controlled release matrix formulation, and solid dosage forms prepared therefrom, preferably for once daily oral administration. The hydrophilic controlled release formulation comprises pregelatinized starch, one or more active ingredients, one or more viscous hydrophilic polymers and optionally pharmaceutically acceptable formulating agents. Preferred hydrophilic polymers include hydroxypropyl cellulose and hydroxypropyl methylcellulose.
    Type: Grant
    Filed: April 1, 2009
    Date of Patent: November 26, 2013
    Assignee: Janssen Pharmaceutica, N.V.
    Inventors: Roger Petrus Gerebern Vandecruys, Eugene Marie Jozef Jans
  • Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
    Patent number: 8101629
    Abstract: The present invention relates to a pharmaceutical composition comprising as active ingredient the hydrochloric acid salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethyl-phenyl]amino]-2-pyrimidinyl]amino]benzonitrile and to processes for their preparation.
    Type: Grant
    Filed: July 28, 2010
    Date of Patent: January 24, 2012
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Jérôme Emile Georges Guillemont, Paul Theodoor Agnes Stevens, Alex Herman Copmans, Jozef Peeters, Alfred Elisabeth Stappers, Roger Petrus Gerebern Vandecruys, Paul Stoffels
  • Amorphous Salt of a Macrocyclic Inhibitor of HCV
    Publication number: 20110306634
    Abstract: The amorphous form of the sodium salt of the macrocyclic inhibitor of HCV of formula: as well as processes for manufacturing this salt.
    Type: Application
    Filed: February 26, 2010
    Publication date: December 15, 2011
    Inventors: Peter Jozef Maria Van Remoortere, Roger Petrus Gerebern Vandecruys, Herman De Kock
  • Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
    Patent number: 7956063
    Abstract: The present invention relates to a pharmaceutical composition comprising as active ingredient the hydrochloric acid salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethyl-phenyl]amino]-2-pyrimidinyl]amino]benzonitrile and to processes for their preparation.
    Type: Grant
    Filed: July 7, 2008
    Date of Patent: June 7, 2011
    Assignee: Janssen Pharmaceutica NV
    Inventors: Jérôme Emile Georges Guillemont, Paul Theodoor Agnes Stevens, Alex Herman Copmans, Jozef Peeters, Alfred Elisabeth Stappers, Roger Petrus Gerebern Vandecruys, Paul Stoffels
  • SALT OF 4-[[4-[[4-(2-CYANOETHENYL)-2,6-DIMETHYLPHENYL]AMINO]-2-PYRIMIDINYL]AMINO]BENZONITRILE
    Publication number: 20110008434
    Abstract: The present invention relates to a pharmaceutical composition comprising as active ingredient the hydrochloric acid salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethyl-phenyl]amino]-2-pyrimidinyl]amino]benzonitrile and to processes for their preparation.
    Type: Application
    Filed: July 28, 2010
    Publication date: January 13, 2011
    Inventors: Jérôme Emile Georges GUILLEMONT, Paul Theodoor Agnes Stevens, Alex Herman Copmans, Jozef Peeters, Alfred Elisabeth Stappers, Roger Petrus Gerebern Vandecruys, Paul Stoffels
  • Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
    Patent number: 7638522
    Abstract: The present invention relates to a pharmaceutical composition comprising as active ingredient the hydrochloric acid salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethyl-phenyl]amino]-2-pyrimidinyl]amino]benzonitrile and to processes for their preparation.
    Type: Grant
    Filed: September 2, 2005
    Date of Patent: December 29, 2009
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Jérôme Emile Georges Guillemont, Paul Theodoor Agnes Stevens, Alex Herman Copmans, Jozef Peeters, Alfred Elisabeth Stappers, Roger Petrus Gerebern Vandecruys, Paul Stoffels
  • FUMARATE OF 4- [[4- [[4- (2-CYANOETHENYL) -2,6-DIMETHYLPHENYL)AMINO] -2-PYRIMIDINYL]AMINO]BENZONITRILE
    Publication number: 20090215804
    Abstract: The present invention relates to the fumarate salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile, pharmaceutical compositions comprising as active ingredient said salt and to processes for their preparation.
    Type: Application
    Filed: September 2, 2005
    Publication date: August 27, 2009
    Inventors: Paul Theodoor Agnes Stevens, Jozef Peeters, Roger Petrus Gerebern Vandecruys, Alfred Elisabeth Stappers, Alex Herman Copmans
  • Pregelatinized Starch In A Controlled Release Formulation
    Publication number: 20090191266
    Abstract: The present invention concerns the use of pregelatinized starch to prevent dose-dumping from a hydrophilic controlled release formulation. It also concerns a hydrophilic controlled release formulation, more in particular a hydrophilic controlled release matrix formulation, and solid dosage forms prepared therefrom, preferably for once daily oral administration. The hydrophilic controlled release formulation comprises pregelatinized starch, one or more active ingredients, one or more viscous hydrophilic polymers and optionally pharmaceutically acceptable formulating agents. Preferred hydrophilic polymers include hydroxypropyl cellulose and hydroxypropyl methylcellulose.
    Type: Application
    Filed: April 1, 2009
    Publication date: July 30, 2009
    Applicant: JANSSEN PHARMACEUTICA N.V.
    Inventors: Roger Petrus Gerebern Vandecruys, Eugene Marie Jozef Jans
  • SALT OF 4-[[4-[[4-(2-CYANOETHENYL)-2,6-DIMETHYLPHENYL]AMINO]-2-PYRIMIDINYL]AMINO]BENZONITRILE
    Publication number: 20090012108
    Abstract: The present invention relates to a pharmaceutical composition comprising as active ingredient the hydrochloric acid salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethyl-phenyl]amino]-2-pyrimidinyl]amino]benzonitrile and to processes for their preparation.
    Type: Application
    Filed: July 7, 2008
    Publication date: January 8, 2009
    Inventors: Jerome Emile Guillemont, Paul Theodoor Agnes Stevens, Alex Herman Copmans, Jozef Peeters, Alfred Elisabeth Stappers, Roger Petrus Gerebern Vandecruys, Paul Stoffels
  • Pellets having a core coated with an antifungal and a polymer
    Publication number: 20040081696
    Abstract: The present invention is concerned with pellets comprising a 710-1180 &mgr;m (16-25 mesh) sugar core, a coating film of a water-soluble polymer and an antifungal agent, and a seal coating layer wherein the residual concentration of dichloromethane is below 600 ppm; pharmaceutical dosage forms comprising said pellets and a method of preparing said pellets.
    Type: Application
    Filed: October 15, 2003
    Publication date: April 29, 2004
    Applicant: Janssen Pharmaceutica N.V.
    Inventors: Paul Marie Victor Gilis, Valentin Florent Victor De Conde, Roger Petrus Gerebern Vandecruys
  • Pregelatinized starch in a controlled release formulation
    Publication number: 20040062805
    Abstract: The present invention concerns the use of pregelatinized starch to prevent dose-dumping from a hydrophilic controlled release formulation. It also concerns a hydrophilic controlled release formulation, more in particular a hydrophilic controlled release matrix formulation, and solid dosage forms prepared therefrom, preferably for once daily oral administration. The hydrophilic controlled release formulation comprises pregelatinized starch, one or more active ingredients, one or more viscous hydrophilic polymers and optionally pharmaceutically acceptable formulating agents. Preferred hydrophilic polymers include hydroxypropyl cellulose and hydroxypropyl methylcellulose.
    Type: Application
    Filed: September 30, 2003
    Publication date: April 1, 2004
    Inventors: Roger Petrus Gerebern Vandecruys, Eugene Marie Jozef Jans
  • Pregelatinized starch in a controlled release formulation
    Patent number: 6667060
    Abstract: The present invention concerns the use of pregelatinized starch to prevent dose-dumping from a hydrophilic controlled release formulation. It also concerns a hydrophilic controlled release formulation, more in particular a hydrophilic controlled release matrix formulation, and solid dosage forms prepared therefrom, preferably for once daily oral administration. The hydrophilic controlled release formulation comprises pregelatinized starch, one or more active ingredients, one or more viscous hydrophilic polymers and optionally pharmaceutically acceptable formulating agents. Preferred hydrophilic polymers include hydroxypropyl cellulose and hydroxypropyl methylcellulose.
    Type: Grant
    Filed: September 28, 2001
    Date of Patent: December 23, 2003
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Roger Petrus Gerebern Vandecruys, Eugene Marie Jozef Jans
  • Pellets having a core coated with an antifungal and a polymer
    Patent number: 6663901
    Abstract: The present invention is concerned with pellets comprising a 710-1180 &mgr;m (16-25 mesh) sugar core, a coating film of a water-soluble polymer and an antifungal agent, and a seal coating layer wherein the residual concentration of dichloromethane is below 600 ppm; pharmaceutical dosage forms comprising said pellets and a method of preparing said pellets.
    Type: Grant
    Filed: June 27, 2000
    Date of Patent: December 16, 2003
    Assignee: Janssen Pharmaceutical N.V.
    Inventors: Paul Marie Victor Gilis, Valentin Florent Victor De Conde, Roger Petrus Gerebern Vandecruys
  • PHARMACEUTICAL COMPOSITIONS COMPRISING CYCLODEXTRINS
    Publication number: 20020150616
    Abstract: The invention provides a novel pharmaceutical composition comprising a no more than sparingly water-soluble drug compound, a cyclodextrin, a physiologically tolerable water-soluble acid, and a physiologically tolerable water-soluble organic polymer.
    Type: Application
    Filed: December 2, 1999
    Publication date: October 17, 2002
    Inventor: ROGER PETRUS GEREBERN VANDECRUYS